AstraZeneca Makes $10bn Offer for Obesity Drugmaker Rhythm Pharmaceuticals

AstraZeneca has made a non-binding offer worth approximately US$10 billion to acquire US-based Rhythm Pharmaceuticals, in a move that could strengthen the British drugmaker’s rare-disease portfolio and expand its presence in the obesity treatment market.

The proposal is valued at as much as US$134 per Rhythm share, including payments linked to the achievement of specified milestones, according to three people familiar with the matter cited by Reuters. The reported offer follows an earlier proposal of US$124 per share made last month, according to a Wall Street Journal report.

Neither company has publicly confirmed an agreement. AstraZeneca declined to comment on the reported approach, while Rhythm did not respond to Reuters’ request for comment.

Rhythm shares closed 28% higher at US$110.68 following news of the offer on 4 November, giving the company a market capitalisation of approximately US$7.64 billion.

Alexion could lead AstraZeneca’s acquisition strategy

The potential acquisition would be pursued through Alexion, AstraZeneca’s rare-disease business, according to two people familiar with the matter.

AstraZeneca acquired Alexion in 2021 for approximately US$39 billion, expanding its operations beyond its established oncology and biopharmaceutical businesses. The unit has since become a central part of the group’s strategy to develop and commercialise treatments for rare diseases.

Rhythm’s portfolio could complement this business through its focus on rare neuroendocrine and metabolic disorders, including severe forms of obesity.

The company develops treatments targeting conditions associated with disruptions to the melanocortin-4 receptor (MC4R) pathway, which plays a role in regulating hunger and energy balance. Its lead commercial product, IMCIVREE (setmelanotide), is approved for certain rare genetic obesity conditions and acquired hypothalamic obesity.

An acquisition would give AstraZeneca access to an established commercial product and a pipeline of investigational treatments in a specialist area of metabolic medicine.

IMCIVREE approval expands Rhythm’s commercial opportunity

A significant development for Rhythm came in March 2026, when the US Food and Drug Administration expanded the approved use of IMCIVREE to include acquired hypothalamic obesity.

The condition is a rare form of obesity caused by damage or dysfunction of the hypothalamus, a region of the brain involved in regulating appetite and body weight. The FDA approval made IMCIVREE the first approved treatment in the United States for this condition.

The approval was supported by results from the Phase 3 TRANSCEND clinical trial, which reported an 18.4% placebo-adjusted reduction in body mass index.

Rhythm’s commercial performance has also provided evidence of demand for the treatment. In its third-quarter 2026 results, the company reported global IMCIVREE revenue of US$92.1 million, an increase of 29% compared with the second quarter.

The company said more than 700 patient start forms for the acquired hypothalamic obesity indication had been received from more than 500 prescribers by 30 September 2026. The number of patients receiving reimbursed therapy globally increased by 20% compared with the previous quarter.

The United States accounted for US$67.5 million, or 73%, of third-quarter product revenue. Rhythm also reported that Japan had approved IMCIVREE for acquired hypothalamic obesity in August 2026.

These developments have broadened the commercial potential of Rhythm’s portfolio beyond its original focus on ultra-rare genetic forms of obesity.

AstraZeneca seeks growth through specialist medicines

The reported offer comes as AstraZeneca seeks to maintain its growth trajectory amid clinical trial setbacks and investor scrutiny of its development pipeline.

Chief Executive Pascal Soriot has been working to reinforce the company’s longer-term growth strategy. AstraZeneca has a substantial presence in oncology, cardiovascular, renal and metabolic diseases, respiratory and immunology, as well as rare diseases.

The reported interest in Rhythm is consistent with a strategy of adding specialist medicines that can complement existing research, development and commercial capabilities.

Jefferies analyst Michael Leuchten described AstraZeneca’s approach of seeking rare-disease assets that fit its existing business footprint as sensible, according to Reuters.

The acquisition would also add exposure to obesity treatments at a time when pharmaceutical companies are competing to develop medicines for a market dominated by major players including Eli Lilly and Novo Nordisk.

Obesity drug market attracts pharmaceutical investment

The global obesity treatment market has become one of the pharmaceutical industry’s major areas of investment, driven by demand for medicines that support weight management and address associated metabolic conditions.

Eli Lilly and Novo Nordisk have established leading positions with their widely used obesity and diabetes treatments. Industry expectations that annual sales across the obesity drug market could exceed US$100 billion over the next decade have encouraged pharmaceutical companies to expand their research pipelines and pursue acquisitions and licensing agreements.

Rhythm operates in a more specialised segment of this market. Its treatments target rare genetic and neuroendocrine conditions associated with severe obesity rather than the broader population seeking weight-loss medicines.

That distinction could provide AstraZeneca with a complementary position in a market where treatment development increasingly spans different patient groups and biological pathways.

For AstraZeneca, the potential transaction would combine Rhythm’s specialist product portfolio and clinical pipeline with Alexion’s rare-disease infrastructure.

Deal uncertainty remains a key consideration

The reported US$10 billion proposal remains non-binding, and there is no publicly confirmed agreement between the companies.

The reported consideration of up to US$134 per share includes milestone payments, meaning the headline value should not be interpreted as an unconditional upfront payment.

The difference between the reported earlier US$124-per-share proposal and the subsequent offer also indicates that negotiations may have evolved, although the companies have not disclosed their positions.

Any transaction would be subject to further negotiations and the relevant corporate and regulatory processes if an agreement is reached.

The next developments to watch include whether AstraZeneca increases or formalises its proposal, whether other pharmaceutical companies express interest in Rhythm, and how the target’s commercial performance and clinical pipeline influence its valuation.

For AstraZeneca, the potential acquisition represents an opportunity to expand its rare-disease business while gaining a stronger position in a specialist segment of the obesity treatment market. However, the outcome will depend on the terms of any final agreement and the future commercial and clinical performance of Rhythm’s medicines.

Follow B2B Market Signal on social media for the latest business news, industry developments, market intelligence and analysis. Connect with us on LinkedIn and follow us on Instagram at @b2bmarketsignal for regular updates